Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT01658995 Completed - Clinical trials for ESI-related Bleeding

Management of Etonogestrel Subdermal Implant-related Bleeding

Start date: September 13, 2012
Phase: Phase 3
Study type: Interventional

This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.

NCT ID: NCT01658124 Completed - Clinical trials for Gastrointestinal Bleeding

Haemorrhage Alleviation With Tranexamic Acid- Intestinal System

HALT-IT
Start date: July 2013
Phase: Phase 3
Study type: Interventional

Severe bleeding in the digestive system is a common symptom of many diseases. Each year, about 50,000 people end up in British hospitals because of this problem and about 5,000 of them die. The most common cause of this bleeding is stomach ulcers. In sub-Saharan Africa, schistosomiasis (parasitic worms) is responsible for about 130,000 deaths from stomach bleeding each year. From previous research in other bleeding conditions such as surgery and trauma, we know that a drug called tranexamic acid can reduce bleeding and save lives. We now want to do the HALT-IT trial to see if giving tranexamic acid can save lives and if there are any complications in people with severe bleeding from the digestive system.

NCT ID: NCT01656317 Completed - SAH Clinical Trials

Rehabilitation of Patients After Subarachnoid Hemorrhage

SAH
Start date: January 1, 2012
Phase: N/A
Study type: Interventional

The study's main objective will be to assess which effect early initiated rehabilitation has on the frequency of complications and the level of physical and cognitive functioning after aneurysmal subarachnoid hemorrhage (SAH). To this end the following aspects will be investigated: The frequency of complications (with special emphasis on pulmonary complications,thromboembolic events, cerebral vasospasm, unintended discontinuation of drains and lines) - Length of stay in hospitals and socio-economic impact - Physical and cognitive function in the early and chronic phase after SAH - Health-related quality of life and participation in society in the chronic phase

NCT ID: NCT01653769 Completed - Aortic Dissection Clinical Trials

CoSeal for Hemostasis of Aortic Anastamoses

Start date: June 2012
Phase: N/A
Study type: Observational

Surgery on the aorta can be associated with significant blood loss. Most commonly this is due to bleeding at the site of aortic anastomosis. Surgical bleeding is associated with significant morbidity. One way to prevent bleeding is to use a special glue (sealant) after performing large connections on the aorta. The goal of this study is to compare the different methods surgeons use to stop/prevent bleeding. The study team will collect medical information about patients before, during, and after surgery on their aortas, including the methods used to prevent bleeding. This information may help doctors improve the way that they care for these patients.

NCT ID: NCT01651130 Completed - Clinical trials for Postpartum Hemorrhage

Carbetocin at Elective Cesarean Delivery Part 3

Start date: June 2012
Phase: N/A
Study type: Interventional

Post-partum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the most common uterotonic drug used to prevent and treat PPH in North America, however, there are some limitations to its use. Oxytocin has a very short duration of action, which requires a continuous infusion to achieve sustained uterotonic activity. The Society of Obstetricians and Gynecologists of Canada (SOGC) has recently recommended a single 100mcg dose of carbetocin at elective Cesarean delivery to promote uterine contraction and prevent post partum hemorrhage (PPH), in lieu of the more traditional oxytocin regimens. Carbetocin lasts 4 to 7 times longer than oxytocin, with a similar side effect profile and apparent greater efficacy rate. However, a dose response study to determine the minimum effective dose of carbetocin has not yet been published. The investigators hypothesize that the minimum effective dose (ED90) is at least 20mcgs (or perhaps below) in women undergoing elective Cesarean delivery.

NCT ID: NCT01647581 Completed - Polypectomy Clinical Trials

Risk of Post-polypectomy Bleeding With Prophylactic Hemoclipping

Start date: September 1, 2011
Phase: N/A
Study type: Interventional

A randomized trial aimed at determining whether or not hemoclips are effective in preventing post-polypectomy bleeds on polyps that are 10mm in size or greater.

NCT ID: NCT01646060 Completed - Healthy Clinical Trials

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

Start date: November 2011
Phase: Phase 1
Study type: Interventional

Zynex's blood volume monitor (BVM) is a non-invasive monitoring device to monitor blood volume and blood loss of a patient during surgery, post operatively and/or in recovery. This monitoring device will identify baseline blood volume and relative changes in blood volume using a specific algorithm to compare and review data already monitored during surgery, displaying blood volume and blood loss in real-time.

NCT ID: NCT01643135 Completed - Bleeding Clinical Trials

Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid

Start date: June 2012
Phase: Phase 4
Study type: Interventional

Tranexamic acid has benn widely used to reduce perioperative bleeding in several operations such as cardiac surgery, liver transplant and joint arthroplasty with good results. Few studies in laminectomy had conflicting results and varying in doses. The objective is to compare perioperative bleeding in major laminectomy between patients receive doubles doses of tranexamic acids (15 mg/kg and 15 mg/kg) with who receive pacebo (0.9% NaCl).

NCT ID: NCT01639833 Completed - Hemorrhage Clinical Trials

A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Verisetâ„¢ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery

Start date: August 2012
Phase: N/A
Study type: Interventional

The objective of this study is to assess the safety and effectiveness of Verisetâ„¢ Hemostatic Patch in cardiovascular procedures by comparing Verisetâ„¢ Hemostatic Patch to TachoSil® in subjects undergoing open cardiovascular surgery involving the aorta (e.g., aortic valve replacement (AVR), David procedure, Bentall procedure, abdominal aortic aneurysm repair, etc.), or CABG.

NCT ID: NCT01634828 Recruiting - Clinical trials for Improved Intraoperative Blood Loss Estimates

Method for Improved Intraoperative Blood Loss Estimates

EBL
Start date: July 2012
Phase: N/A
Study type: Observational

The purpose of this study is to develop a mathematical algorithm which the investigators plan to use to more accurately estimate intraoperative blood loss.